Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 8/20 | 0.37 |
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10976991 | 0.75 | GABBR2 (0.52) | LAP3METAP1GABBR2GABBR1MMP2 | |
| SCHEMBL26310679 | 0.75 | LAP3 (0.42) | LAP3FDPSMETAP1GABBR2GABBR1 | |
| SCHEMBL19212007 | 0.74 | LAP3 (0.46) | LAP3FDPSMETAP1CA12CA1 | |
| SCHEMBL8015730 | 0.74 | LAP3 (0.46) | LAP3FDPSMETAP1MMP1MMP2 | |
| SCHEMBL16797954 | 0.72 | LAP3 (0.44) | LAP3FDPSMETAP1MMP1MMP2 | |
| SCHEMBL28539152 | 0.72 | LAP3 (0.44) | LAP3FDPSMETAP1MMP1MMP2 | |
| SCHEMBL2787540 | 0.72 | GABBR2 (0.46) | GABBR2GABBR1MMP2FOLH1 | |
| SCHEMBL7961190 | 0.70 | LAP3 (0.48) | LAP3FDPSMETAP1GABBR2GABBR1 | |
| SCHEMBL2850492 | 0.70 | LAP3 (0.54) | LAP3FDPSMETAP1 | |
| SCHEMBL30585641 | 0.70 | LAP3 (0.42) | LAP3FDPSMETAP1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3413934-B1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2021-10-13 | — | — | EP | claimed |
| CN-109195641-B | Improved implant treatment with phosphonic acid compounds | 纳米桥接分子股份公司 | 2021-07-27 | — | — | CN | claimed |
| US-11000627-B2 | Treatment of implants with phosphonic acid compounds | NANO BRIDGING MOLECULES SA (CH) | 2021-05-11 | — | — | US | claimed |
| US-20190038802-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2019-02-07 | — | — | US | claimed |
| EP-3413934-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | Nano Bridging Molecules SA (CH) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137623-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2017-08-17 | — | — | WO | claimed |
| EP-3413934-B1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2021-10-13 | — | — | EP | disclosed |
| CN-109195641-B | Improved implant treatment with phosphonic acid compounds | 纳米桥接分子股份公司 | 2021-07-27 | — | — | CN | disclosed |
| US-11000627-B2 | Treatment of implants with phosphonic acid compounds | NANO BRIDGING MOLECULES SA (CH) | 2021-05-11 | — | — | US | disclosed |
| US-20190038802-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2019-02-07 | — | — | US | disclosed |
| EP-3413934-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | Nano Bridging Molecules SA (CH) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137623-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2017-08-17 | — | — | WO | disclosed |